Lilly's stock leads S&P 500 losers as Mounjaro, Zepbound sales to miss forecasts
Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter revenue guidance that was below Wall Street expectations,
2don MSN
The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
Eli Lilly blamed the shortfall on lower-than-anticipated demand for its weight-loss drugs. Indeed, the drug maker ...
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback